NCT00949078

Omalizumab in the Treatment of Peanut Allergy

Effects of Omalizumab on Peanut Allergen Induced Cellular and Clinical Responses in Peanut Allergic Adults

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: Johns Hopkins University · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if treatment with omalizumab (Xolair, anti-IgE) can eliminate or reduce symptoms of peanut allergy.

Detailed description

The study will evaluate if omalizumab is an effective treatment for peanut allergy. In addition we will further evaluate the role of allergic cells (mast cells and basophils) and IgE in food allergy.

Conditions

• Food Allergy
• Peanut Allergy

Interventions

Type	Name	Description
DRUG	omalizumab	omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE

Timeline

• Start date: 2009-07-01
• Primary completion: 2011-08-01
• Completion: 2011-08-01
• First posted: 2009-07-30
• Last updated: 2017-07-12
• Results posted: 2017-07-12

Locations

1 site across 1 country: United States